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Abstract A stop codon at position 322 was introduced to gen-
erate a truncated, C-terminal-deleted AT2 receptor. Expression
studies in Xenopus oocytes showed that C-terminal-deleted
AT2 had reduced a⁄nity to [125I]angiotensin II (Kd = 1.7 nM)
and enhanced binding of the AT2-speci¢c peptidic ligand
[125I]CGP42112A (Kd = 0.097 nM). AT2 activation by angioten-
sin II resulted in reduction of cGMP levels in oocytes and this
reduction was further enhanced by C-terminal deletion, implying
that the C-terminus may have a negative e¡ect on the AT2-
mediated cGMP reduction. Moreover, interaction of the AT2
with the ATP-binding domain of the human ErbB3 receptor in
yeast two-hybrid assay was abolished by C-terminal deletion. In
summary, the C-terminal cytoplasmic tail of AT2 modulates its
ligand binding and signaling properties. 3 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Angiotensin II (Ang II) has long been recognized as an im-
portant component of the neuroendocrine control of cardio-
vascular function [1^3]. The two receptor subtypes of Ang II,
AT1 and AT2, share structural similarity (both are proteins
with seven transmembrane topology) and 34% homology at
the amino acid level [4^7]. Most of the well-known physiolog-
ical e¡ects caused by Ang II, including vasoconstriction, water
and sodium intake and induction of cell growth, are mediated
via the receptor type AT1. The AT1 receptor is known to
activate Gi and Gq proteins, Jak/STAT proteins and mito-
gen-activated protein kinases [4^12]. The C-terminal cytoplas-
mic tail of the AT1 is implicated in its ability to couple to Gi
protein, phospholipase CQ and Jak/STAT proteins [13^15].
The YIPP motif (amino acids 319^322) in the C-terminal cy-
toplasmic tail of the AT1 is shown to be essential for its
interaction with Jak2. The nuclear localizing signal (NLS) of
AT1 (KKFKK, amino acids 307^311) seems to be needed for
nuclear translocation of this receptor upon Ang II activation
[16,17]. Moreover, the STL motif (amino acids 335^337) is
essential for the internalization of the AT1 receptor upon
Ang II activation [18]. In summary, a substantial body of
literature that sheds light on the structure^function relation-
ship of the C-terminal cytoplasmic tail of the AT1 exists.
The AT2 receptor is a 363 amino acid protein and many of
the amino acids that are functionally important for the AT1
receptor are conserved in AT2. Indeed, the roles of conserved
residues such as Arg182 in the second extracellular loop,
Asp297 in the third extracellular loop, Lys215 in the ¢fth
transmembrane domain, and His273 and Asp279 in the sixth
transmembrane domain in ligand binding to AT2 are well-
established [19^24]. However, AT1 and AT2 di¡er in several
aspects. While the mechanisms involved in AT1 internaliza-
tion are well delineated, thus far there is no evidence to sug-
gest that AT2 becomes internalized upon Ang II activation
([25] and references therein). The AT2 receptor is expressed at
high levels, but in a transient manner, during fetal develop-
ment and during the ¢rst few weeks after birth [26,27].
Although these observations imply an important role for the
AT2 receptor in embryogenesis and in the development of
speci¢c neuronal pathways, the exact physiological role of
this receptor is currently unclear. Several studies indicate an
important role for AT2 in kidney and urinary tract develop-
ment [28,29]. The adult tissues including kidney, uterus, pan-
creas, heart and adrenal medulla also have high level expres-
sion of this receptor [30,31]. In general, activation of AT2 by
Ang II seems to inhibit the physiological e¡ects resulting from
the activation of AT1 by Ang II [32,33]. For example, while
binding of Ang II to AT1 activates cell growth, AT2 activa-
tion by Ang II inhibits cell growth and induces apoptosis in
many cell types. AT2 is also shown to directly interact with
other membrane-bound proteins including AT1 and the hu-
man ErbB3 receptor [34^36]. We have shown previously that
a truncated rat AT2 receptor that contained the amino acids
226^363 could interact with the ATP-binding domain of the
human ErbB3 receptor in a yeast two-hybrid protein^protein
interaction assay [36]. Since this region spanned the third in-
tracellular loop and the C-terminal cytoplasmic tail of AT2,
this result implied that the C-terminal cytoplasmic tail of AT2
may be directly involved in this interaction. As mentioned
above, while the functional role of the C-terminal cytoplasmic
tail of the AT1 receptor is well-established, currently not
much information is available regarding the functional role
of the C-terminal cytoplasmic tail of AT2. A comparison of
the C-terminal cytoplasmic domain of AT1 and AT2 is given
in Fig. 1. In an attempt to de¢ne the functional role of the C-
terminal cytoplasmic tail of AT2, we have generated a trun-
cated AT2 receptor in which a stop codon was introduced at
position 322 (Fig. 2). The ligand-binding and signaling prop-
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erties of this truncated AT2 were analyzed by expressing them
in Xenopus oocytes. The ability of the truncated AT2 to in-
teract with the human ErbB3 receptor was assessed using
yeast two-hybrid assay. Our results indicate that the C-termi-
nal cytoplasmic tail is important for both ligand binding and
signaling by the AT2 receptor.
2. Materials and methods
2.1. Materials
Radiolabeled material for sequencing and binding studies
([35S]dATP, [125I]Ang II, [125I]CGP42112A) and cGMP RIA kit
were obtained from NEN Life Science Products (Boston, MA,
USA). Oligonucleotides used for sequencing and mutagenesis were
purchased from Gibco BRL Life Technologies (Gaithersburg, MD,
USA). The other kits that were used in this study were Quick Change
site-directed mutagenesis kit (Stratagene Products, La Jolla, CA,
USA), DTth DNA polymerase sequencing kit (Clontech, Palo Alto,
CA, USA) and Riboprobe Gemini in vitro transcription system
(Promega, Madison, WI, USA). Female Xenopus were obtained
from Nasco (Fort Atkinson, WI, USA).
2.2. Strains, plasmids and growth conditions
The growth conditions for Escherichia coli strains TG1 and HB101
and Saccharomyces cerevisiae strains CG1945, Y190 and HF7C were
as described previously [36^38]. Ampicillin was used to a ¢nal con-
centration of 50 Wg/ml and kanamycin was used to a ¢nal concentra-
tion of 25 Wg/ml wherever selection was made.
2.3. Construction of C-terminal-deleted AT2
The C-terminal-deleted AT2 receptor was generated by using the
Quick Change site-directed polymerase chain reaction mutagenesis
kit. The oligonucleotide primers used to introduce a stop codon at
position 322 of the open reading frame of AT2 were 5P-CCCTTCC-
TGTATTGTTTCGTTTGAAACCGC-3P and 5P-GCGGTTTCAAA-
CGAAACAATACAGGAAGGG-3P and the mutagenesis was carried
out according to instructions provided with the kit. The parental
DNA template was the pSP64 polyA plasmid carrying the DNA
specifying open reading frame (ORF) of the rat AT2 [20]. The
pSP64 polyA plasmid carrying the C-terminal-deleted AT2 DNA
was designated pBG5001.
2.4. In vitro transcription, expression in Xenopus oocytes,
ligand-binding studies and cGMP assay
To generate cRNAs corresponding to the wild-type and mutant
AT2 receptor genes, in vitro transcription of the pSP64 polyA vectors
carrying the wild-type and mutant AT2 receptor genes was carried out
using ’Riboprobe Gemini Systems’. Techniques for injection of cRNA
were performed as described previously [20]. Oocytes were microin-
jected with 50 nl of cRNA solution at a concentration of 1 mg/ml and
after 2 days were treated with collagenase (0.5 mg/ml) for 18 min [20].
The residual follicular cells were removed manually. It is known that
some donor frogs yield oocytes that have Ang II receptors in their
membrane [39]. Therefore, for these experiments, we selected oocytes
that did not have endogenous Ang II receptors. This was done by
screening the oocytes from each donor frog by performing binding
experiments with [125I]Ang II. During the 4 days before binding ex-
periments, the oocytes were maintained in Barth’s medium [39] with
continuous renewal of the medium for every 4^6 h. For binding ex-
periments, the oocytes were washed with Barth’s medium before in-
cubating in the pre-incubation bu¡er [20]. Under these experimental
conditions, no evidence for endogenous Ang II-like peptides was ob-
served. For cGMP assay, groups of ¢ve oocytes were used per sample.
The experiment was done in triplicate and was repeated using samples
from three di¡erent donors. The cells were exposed to 50 nM Ang II
in pre-incubation bu¡er for 5 min. To achieve blocking of Ang II
binding with PD123319, a 15 min pre-incubation in the presence of
PD123319 was performed before the addition of Ang II. At the end of
the treatment with Ang II, the £uid was removed and the cells were
subjected to £ash-freezing in liquid nitrogen. Cells were stored at
370‡C until the radioimmunoassay was performed according to the
instructions of the cGMP RIA kit purchased from NEN Life Science
Products.
2.4.1. Yeast two-hybrid assay. The strategy used to construct a
fusion protein in which the yeast GAL4 DNA-binding domain was
fused to the C-terminal-deleted AT2, was similar to that described
previously [36]. The oligonucleotide primers corresponding to the 5P
region of the rat AT2 ORF (5P-GAAGGACAACTTCAGTTTGC-3P)
and the 3P region of the C-terminal-deleted AT2 (5P-GCGG-
TTTCAAACGAAACAATACAGGAAGGG-3P) were used to ampli-
fy the nucleotide sequence of the ORF of C-terminal-deleted rat AT2
receptor from plasmid pBG5001 which was cloned in pCR02.1 ini-
tially. This fragment was then subcloned as an EcoRI fragment into
the EcoRI-digested pGBKT7 to generate translational fusion of the
C-terminal-deleted AT2 with the GAL4 DNA-binding domain and
the sequence at the junction was veri¢ed by dideoxynucleotide se-
quencing. The plasmid pBGKT7 harboring GAL4 BD:C-terminal-
deleted AT2 translation fusion was designated pBG5003. Plasmids
pBG857 (in which the yeast GAL4 transcription activation domain
was fused to the ATP-binding domain of the ErbB3 receptor) and
pBG1101 (in which the truncated AT2 (AT2226363) was fused to
Gal4 BD) were described previously [36]. The plasmid pBG1157 car-
ried a translation fusion of the complete AT2 receptor with the GAL4
BD of pGBKT7. This was constructed using a strategy similar to that
used for the construction of pBG877 [36]. The transformation of the
S. cerevisiae strains CG1945 or HF7C with the ‘bait’ vector pBG5003
and prey plasmid pBG857, and analysis of interaction between the C-
terminal-deleted AT2 and the ATP-binding domain of the ErbB3 by
yeast two-hybrid assay was carried out using methods described pre-
viously [36].
3. Results and discussion
3.1. Ligand-binding properties of the C-terminal-deleted AT2
To determine whether deleting the C-terminal cytoplasmic
domain of the rat AT2 receptor in£uences the ligand-binding
properties of AT2, we microinjected equal amounts of cRNA
corresponding to wild-type AT2 or C-terminal-deleted AT2
into Xenopus laevis oocytes. The ability of these receptors to
bind the peptidic ligands [125I]Ang II and [125I]CGP42112A
(AT2-speci¢c ligand) and the non-peptidic AT2-speci¢c ligand
PD123319 was evaluated by binding assays. Collagenase treat-
ment followed by manual removal of any residual follicular
layer was carried out prior to ligand-binding experiments.
Previously we have shown that rat AT2 receptors expressed
in Xenopus oocytes seem to have retained all the binding
properties that are reported for them when they are expressed
in mammalian cells [20]. The C-terminal-deleted AT2 retained
its ability to bind [125I]Ang II, [125I]CGP42112A and
PD123319 (Fig. 3), but demonstrated di¡erences in its a⁄nity
to the peptidic ligands when compared to the a⁄nity of the
wild-type AT2 to these ligands. The C-terminal-deleted AT2
showed increased a⁄nity to [125I]CGP42112A (Kd = 0.097
nM) and decreased a⁄nity to [125I]Ang II (Kd = 1.7 nM)
(Fig. 3 and Table 1). These results indicated that the C-ter-
minal cytoplasmic domain of the AT2 plays a role in deter-
Fig. 1. Comparison of the C-terminal cytoplasmic regions of the Ang II receptors AT1 and AT2. The NLS of AT1 (KKFKK, amino acids
307^311) is marked in a rectangular box. The YIPP motif (amino acids 319^322) that interacts with Jak2 is marked by an overline. The STL
motif (amino acids 335^337) is shown in a circle.
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mining the extent of a⁄nity of this receptor to di¡erent pep-
tidic ligands. No signi¢cant di¡erences were observed between
the extent of blocking by PD123319 (at concentrations 0.1
nM, 10 nM and 1 WM) of the binding of [125I]CGP42112A
(at 1.0 nM) to the wild-type AT2 receptor and to the C-ter-
minal-deleted AT2. Therefore, the C-terminal deletion did not
seem to alter (either increase or decrease) the ability of
PD123319 to bind the AT2. Previously we have shown that
even the mutations in the ¢fth transmembrane domain
(Lys215Glu and Lys215Gln) that abolished the ability of the
receptor to bind Ang II and reduced the ability of the receptor
to bind CGP42112A did not a¡ect the ability of the receptor
to bind PD123319 [20]. These results imply that there are
signi¢cant di¡erences between the binding requirements for
the non-peptidic ligand PD123319 and the peptidic ligands
Ang II and CGP42112A.
3.2. cGMP levels of oocytes expressing the wild-type and
C-terminal-deleted AT2
It has been known for some time that activation of the AT2
by Ang II results in altering the cGMP levels in di¡erent cell
types [32]. In neonatal neuronal cells it was shown that acti-
vation of the AT2 by Ang II resulted in decreasing cGMP
levels [40]. AT2 receptor activation is also known to reduce
basal cGMP levels in the neointima of rat aorta after balloon
injury [41]. In PC12W cells it was shown that AT2 receptor
activation by Ang II results in the inhibition of a particulate
guanylate cyclase and concomitant reduction of cGMP levels
[42]. In contrast, in di¡erentiating NG108-15 cells and neuro-
blastoma neuro-2A cells, the AT2 activation by Ang II re-
sulted in activation of a soluble guanylyl cyclase via nitric
oxide synthesis [43,44]. Thus the ability of the AT2 to alter
cGMP levels is di¡erent in di¡erent cell types.
Recently, the renin^angiotensin system has evolved as one
of the many signi¢cant contributing factors in the endocrine
control of ovarian function along with insulin-like growth
factors and binding proteins [45^50]. It was shown that addi-
tion of the AT2 antagonist PD123319 to the perfusate used
for in vitro perfusion of the rabbit ovaries inhibited gonado-
tropin-induced ovulation and oocyte maturation in a dose-
dependent manner. Increases in Ang II levels in the ovary in
response to gonadotropin exposure are also reported. Taken
together, these results suggest that AT2 activation is one of
the contributing factors for oocyte maturation. However, how
AT2 activation by Ang II contributes to the intracellular
changes in oocyte that lead to oocyte maturation is unclear.
Interestingly, a decrease in cGMP levels is known to accom-
pany spontaneous maturation of rat oocytes and microinjec-
tion of cGMP inhibits this spontaneous maturation [51]. Since
the development of Xenopus oocytes parallels the development
of mammalian oocytes and also since the AT2 is capable of
reducing cGMP levels in some cell types, we analyzed whether
rat AT2 activation a¡ected the cGMP levels of Xenopus oo-
cytes. As shown in Fig. 4, when oocytes were not injected with
any cRNA and exposed to Ang II, the levels of cGMP for a
group of ¢ve oocytes was about 1.5 pmol. This was compa-
rable to the levels of cGMP for a group of oocytes that were
not exposed to Ang II (Fig. 4). These uninjected oocytes did
Fig. 2. Location of the stop codon that terminates the translation of AT2 to generate C-terminal-deleted AT2. Predicted organization of the
rat AT2 receptor is shown. Location of the Gly322 (GGA) that was converted to the stop codon (TGA) is marked by the arrow.
Table 1
Binding parameters of [125I]Ang II and [125I]CGP42112A for oocytes injected with the wild-type AT2 receptor and the C-terminal-deleted AT2
Receptor type [125I]Ang II [125I]CGP42112A
Kd (nM) Bmax (fmol/oocyte) Kd (nM) Bmax (fmol/oocyte)
Wild-type AT2 0.15 4.97 0.12 5.03
C-terminal-deleted AT2 1.7 4.89 0.097 5.05
Ligand-binding experiments were carried out using [125I]Ang II or [125I]CGP42112A on oocytes expressing AT2 or C-terminal-deleted AT2 at
concentrations ranging from 0.05 to 2 nM. Four to six oocytes from at least two di¡erent donors were used to obtain each data point to gen-
erate saturation isotherms for the speci¢c binding of these ligands to the oocytes. Scatchard plot analysis was carried out to determine the dis-
sociation constants.
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not show any detectable binding to [125I]Ang II, suggesting
that they did not have any native receptors. When the oocytes
were injected with AT2 and exposed to Ang II, the levels of
cGMP for a group of ¢ve oocytes was reduced to 0.95 pmol
(Fig. 4). However, when a 15 min pre-treatment with
PD123319 was carried out before exposure to Ang II, the
oocytes expressing AT2 showed increased levels of cGMP
(1.59 pmol), which was comparable to that found in the
case of uninjected oocytes (1.5 pmol) (Fig. 4). The decrease
in cGMP levels of the oocytes expressing C-terminal-deleted
AT2 was even more pronounced (Fig. 4). The oocytes express-
ing the C-terminal-deleted AT2 showed reduced cGMP levels
even in the absence of Ang II exposure when compared to the
oocytes expressing the AT2 receptor that were not exposed to
Ang II (Fig. 4). This reduction in cGMP levels in the oocytes
expressing the C-terminal-deleted AT2 was further enhanced
by Ang II activation. The levels of cGMP in these cells were
diminished to 0.45 pmol (for a group of ¢ve oocytes), whereas
this reduction was abolished by treatment with PD123319
(Fig. 4). Thus rat AT2 receptor activated by Ang II seems
to be capable of reducing cGMP levels in Xenopus oocytes.
Moreover, removing the C-terminal cytoplasmic domain of
AT2 did not abolish, but potentiated this function of the
receptor. The observation that even in the absence of Ang
Fig. 3. Ligand-binding properties of the Xenopus oocytes expressing
the wild-type AT2 receptor and the C-terminal-deleted AT2. The
speci¢c bindings of [125I]Ang II and [125I]CGP42112A (ligands at a
concentration of 0.5 nM) to the oocytes expressing wild-type and
mutated receptors are compared. Binding experiments were con-
ducted for a period of 1 h according to the procedures described
previously [20]. Results are shown as relative percentages of the
binding of the appropriate ligand to the oocytes expressing wild-
type AT2 receptor. Receptor expression was quantitated by binding
studies using four to six oocytes from at least three donors (a total
of at least 12 oocytes). Three di¡erent cRNA preparations were
used in these experiments. The standard errors are marked in white
lines. Student’s t-test was performed to determine the signi¢cance
levels for the above data sets. It was found that the extent of bind-
ing of oocytes expressing C-terminal-deleted AT2 to [125I]Ang II (re-
duced a⁄nity) or [125I]CGP42112A (increased a⁄nity) was signi¢-
cantly di¡erent from that of the wild-type since P 6 0.001 for each
data group.
Fig. 4. cGMP levels of the Xenopus oocytes expressing the wild-type
AT2 receptor and the C-terminal-deleted AT2 when activated by
Ang II. Groups of ¢ve oocytes (uninjected or expressing the AT2 or
C-terminal-deleted AT2) were exposed to 50 nM Ang II in the pre-
incubation bu¡er for 30 s. When Ang II binding was blocked with
PD123319, a pre-incubation in the presence of 1 WM PD123319 was
performed before exposure to Ang II. cGMP measurements were
carried out as described in Section 2. Results shown are derived
from experiments using triplicate samples from three di¡erent do-
nors. The standard errors for each data set are marked in black
lines. Student’s t-test showed that P is less than 0.001 for the di¡er-
ences observed between the cGMP levels of (a) uninjected oocytes
exposed to Ang II versus the oocytes expressing AT2 and exposed
to Ang II, (b) uninjected oocytes versus the oocytes expressing the
C-terminal-deleted AT2, (c) uninjected oocytes exposed to Ang II
versus the oocytes expressing the C-terminal-deleted AT2 and ex-
posed to Ang II, and (d) oocytes expressing AT2 and exposed to
Ang II versus oocytes expressing the C-terminal-deleted AT2 and
exposed to Ang II.
Table 2
C-terminal-deleted AT2 does not interact with the ATP-binding domain of the ErbB3 receptor as determined by the growth characteristics and
L-galactosidase activity of the yeast strain HF7C carrying the ‘bait’ plasmids and ‘prey’ plasmids
Plasmid 1: GAL4 BD
translationally fused to
Plasmid 2: GAL4 AD
translationally fused to
Growth on Trp3Leu3
SD
plates
Growth on
Trp3Leu3 His3
3ATþ SD plates
L-Galactosidase
activity
Interacting peptides
pVA3-1 (GAL4 BD:p53) pTD1-1 (GAL4 AD:SV
40 large T antigen)
+++ +++ +++ p53:T antigen, +ve
control
pBG1157 (GAL4 BD:AT2
receptor)
pBG857 (GAL4
AD:ErbB3668782)
+++ ++ ++ AT2 receptor:
ErbB3668782
pBG1101
(GAL4BD:AT2226363)
pBG857 (GAL4
AD:ErbB3668782)
+++ ++ ++ AT2226363 :
ErbB3668782
pBG5003 (GAL4 BD:
C-terminal-deleted AT2)
none (no growth on Trp3
His3 3ATþ SD
3 3 C-terminal-deleted
AT2 receptor alone
pBG5003 (GAL4 BD:
C-terminal-deleted AT2)
pGAD 424 (GAL4 AD
only)
+++ 3 3 C-terminal-deleted
AT2: GAL4 AD
pBG5003 (GAL4 BD:
C-terminal-deleted AT2)
pBG857 (GAL4
AD:ErbB3668782)
+++ 3 3 C-terminal-deleted
AT2: ErbB3668782
+++ indicates positive and 3 indicates negative.
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II activation the C-terminal-deleted rat AT2 receptor was ca-
pable of reducing cGMP levels in Xenopus oocytes, and that
Ang II activation further enhanced this reduction, implied
that the C-terminal cytoplasmic domain of AT2 has a nega-
tive regulatory role on the AT2-mediated cGMP reduction.
This sharp decrease in the cGMP levels of oocytes expressing
either AT2 or C-terminal-deleted AT2 and activated by Ang
II could be observed even when the incubation in the presence
of Ang II was carried out for 1 min. However, when the
incubation was continued for 5 min or more, this e¡ect was
not observed (data not shown).
3.3. Role of C-terminus of the AT2 in the interaction between
the AT2 and the ErbB3
We have shown previously that the region spanning the
ATP-binding domain of the human ErbB3 receptor interacts
with the AT2 receptor in a yeast two-hybrid assay [36]. We
have also shown that a truncated AT2 receptor (spanning
amino acids 226^363) that contains the third intracellular
loop and the C-terminal cytoplasmic region of the AT2 is
su⁄cient for this interaction [36]. To determine whether the
C-terminal cytoplasmic region of the AT2 is essential for this
interaction, we generated a fusion protein in which GAL4 BD
was fused to the C-terminal-deleted AT2 (pBG5003). The bait
plasmid pBG5003 and prey plasmid pBG857 were introduced
into yeast strains CG1945 and HF7C and the transformants
were selected on Trp3Leu3 SD plates. The ability of these
colonies to grow on Trp3Leu3 His3 3ATþ SD plates and
express L-galactosidase activity was compared with the ability
of the yeast colonies carrying plasmid combinations of
pBG1157 (speci¢es GAL4 BD:complete AT2 fusion protein)
and pBG857, or pBG1101 (speci¢es GAL4 BD:AT2226363
fusion protein) and pBG857, to do the same functions. As
shown in Table 2, the yeast transformants of the strain
HF7C that express the GAL4 BD:complete AT2 fusion pro-
tein and GAL4 AD:ErbB366878Þ fusion protein (due to the
presence of pBG1157 and pBG857) were able to grow on
Trp3Leu3 His3 3ATþ SD plates and show L-galactosidase
activity. Similarly, the yeast transformants of HF7C that ex-
press GAL4BD:AT2226363 fusion protein and GAL4
AD:ErbB3668782 fusion protein (due to the presence of
pBG1101 and pBG857) were also able to grow on Trp3Leu3
His3 3ATþ SD plates and show L-galactosidase activity (Ta-
ble 2). However, the yeast transformants of HF7C that ex-
press GAL4 BD:C-terminal-deleted AT2 fusion protein and
GAL4 AD:ErbB3668782 fusion protein (due to the presence
of pBG5003 and pBG857) showed highly reduced growth on
Trp3Leu3 His3 3ATþ SD plates and did not exhibit any
detectable L-galactosidase activity (Table 2). Similar results
were obtained when the yeast transformants of strain
CG1945 with the above-mentioned plasmid combinations
were grown on Trp3Leu3 His3 3ATþ SD plates. These re-
sults suggested that the C-terminal cytoplasmic domain of the
AT2 is needed for optimal interaction between the AT2 and
the ErbB3668782 in a yeast two-hybrid assay.
In summary, our results show that the C-terminal cytoplas-
mic domain of the AT2 plays a signi¢cant role in both ligand-
binding and signaling properties of this receptor. Deleting the
C-terminal cytoplasmic domain reduced high-a⁄nity binding
of AT2 to Ang II, whereas it improved the high-a⁄nity bind-
ing of AT2 to CGP42112A. We and others have shown that
the requirements for high-a⁄nity binding forms of AT2 to
di¡erent peptidic ligands are di¡erent [19^24]. This result is
consistent with this observation and indicates that the C-ter-
minus of AT2 modulates the high-a⁄nity form of the recep-
tor. We have also shown that in Xenopus oocytes, activation
of the rat AT2 can result in reduction of basal cGMP levels.
In rat oocytes, reduction in cGMP levels is a step that is
shown to contribute to oocyte maturation [51]. As mentioned
before, elevating cGMP levels in rat oocytes inhibit oocyte
maturation [51]. The observation that in developing, stage V
Xenopus oocytes, rat AT2 receptor reduces cGMP levels sug-
gests a possible signaling mechanism by which rat AT2 may
assist oocyte maturation. The observation that deleting the C-
terminal cytoplasmic domain improves the ability of AT2 to
reduce cGMP levels further implies that this region may con-
trol the ability of AT2 to activate the signaling pathway lead-
ing to the reduction of cGMP levels. Finally, we also show
that the optimal interaction of AT2 with the ATP-binding
domain of the ErbB3 in yeast two-hybrid assay requires the
C-terminal cytoplasmic domain.
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